Results 81 to 90 of about 17,709 (191)

Temperature Safeguards and Peri‐Procedural Strategies for Stem Cell Collection in Cold Agglutinin Disease: A Case Report and Literature Review

Journal of Clinical Apheresis, Volume 41, Issue 4, August 2026.
ABSTRACT Cold agglutinins can result in red blood cell (RBC) agglutination and lysis at low temperatures. Temperature sensitivity during stem cell mobilization, processing, and infusion poses unique procedural challenges in patients with active cold agglutinins.
S. Bellegarde, C. Scott, R. Sabol, T. Eunson, Z. J. Gahvari, C. P. Onyenekwu   +5 more
wiley   +1 more source

Coexistence of primary myelofibrosis and chronic lymphocytic leukemia

Blood and Lymphatic Cancer: Targets and Therapy, 2014
Sonja Burgstaller, Josef Thaler Klinikum Wels-Grieskirchen, Abteilung für Innere Medizin IV, Wels, AustriaAbstract: Coexistence of two hematologic malignancies in one patient is generally a rare phenomenon.
Burgstaller S, Thaler J
doaj  

Immune Effector Cell‐Associated Hematotoxicity With Secondary Myelofibrosis Following Idecabtagene‐Vicleucel for Multiple Myeloma, Comprehensively Treated With Autologous Hematopoietic Stem Cell Boosting

eJHaem, Volume 7, Issue 4, August 2026.
ABSTRACT Pancytopenia accompanied by chimeric antigen receptor T cell (CAR‐T) therapy is termed immune effector cell‐associated hematopoietic toxicity (ICAHT), which is often sustained and refractory to supportive care. We report a case of a 52‐year‐old man with multiple myeloma who developed severe ICAHT with secondary myelofibrosis (sMF) after ...
Keishi Ogura, Takahiro Fujino, Takahisa Nakamura, Akihiro Miyashita, Akio Onishi, Taku Tsukamoto, Shinsuke Mizutani, Yuji Shimura, Shinichi Fuchida, Junya Kuroda   +9 more
wiley   +1 more source

Impact of Atrial Fibrillation on the Risk of Thrombosis and Bleeding for Patients With Polycythemia Vera and Essential Thrombocytosis in the Real World

American Journal of Hematology, Volume 101, Issue 9, Page 2463-2468, September 2026.
Rodrigo Ortega Perez, Luis Manuel Domínguez Rodríguez, Francisca Ferrer‐Marín, Beatriz Cuevas Ruíz, Clara Martínez Valverde, Patricia Vélez Tenza, María Isabel Mata Vázquez, Adrián Segura Díaz, María Laura Fox, Elvira Mora, Manuel Mateo Pérez Encinas, Mercedes Gasior Kabat, Gonzalo Carreño‐Tarragona, Rafael Andrés del Orbe, Gonzalo Caballero‐Navarro, Elena Magro Mazo, Ana Pardo Sanz, José Luis Zamorano Gómez, Alberto Álvarez Larrán, Valentín Garcia‐Gutierrez   +19 more
wiley   +1 more source

Primary myelofibrosis: current therapeutic options

Revista Brasileira de Hematologia e Hemoterapia
Primary myelofibrosis is a Philadelphia-negative myeloproliferative neoplasm characterized by clonal myeloid expansion, followed by progressive fibrous connective tissue deposition in the bone marrow, resulting in bone marrow failure.
Paula de Melo Campos
doaj   +1 more source

CD34-positive circulating cells quantification during follow-up in myeloproliferative neoplasms

Annals of Hematology
Polycythemia vera (PV) and Essential thrombcythemia (ET) are myeloproliferative neoplasms (MPNs) that can progress to secondary myelofibrosis, a complication associated with increased mortality. Circulating CD34-positive cells at diagnosis can be used to
Marine Demoy, Maxence Bauvais, Agathe Vely, Thomas Nicol, Jérémie Riou, Hortense Le Jeanne, Aurélien Bauduin, Hubert Rambaud, Françoise Boyer, Franck Geneviève, Agathe Boussaroque, Marie-Christine Copin, Valérie Ugo, Corentin Orvain, Damien Luque Paz   +14 more
doaj   +1 more source

The bidirectional relationship between JAK2V617F allele burden and inflammation in polycythaemia vera: Insights from interferon and ruxolitinib therapy

HemaSphere, Volume 10, Issue 8, August 2026.
Tiziano Barbui, Paola Guglielmelli, Alessandro Maria Vannucchi   +2 more
wiley   +1 more source

Reticulosarcomatosis in primary myelofibrosis [PDF]

Cancer, 1968
openaire   +2 more sources

Primary myelofibrosis: risk stratification by IPSS identifies patients with poor clinical outcome

Clinics, 2013
OBJECTIVES: To evaluate whether risk scores used to classify patients with primary myelofibrosis and JAK-2 V617F mutation status can predict clinical outcome.
Bruno Deltreggia Benites, Carolina Silva Costa Lima, Irene Lorand-Metze, Marcia Torresan Delamain, Gislaine Borba Oliveira, Daiane de Almeida, Carmino Antonio de Souza, Jose Vassallo, Katia Borgia Barbosa Pagnano   +8 more
doaj  

Clinical features and treatment of newly diagnosed multiple myeloma with secondary myelofibrosis: a retrospective study

Therapeutic Advances in Hematology
Background: Secondary myelofibrosis (SMF) is characterized by the excessive deposition of fibrous tissue on top of the primary disease, often causing clinical manifestations to be overshadowed by the primary disease.
Han Xu, Yujie Xu, Mengying Wang, Chunxia Mao, Junxia Huang, Tianlan Li, Yan Gao, Shanshan Liu, Jingjing Zhou, Yi Zhang, Xianqi Feng   +10 more
doaj   +1 more source